Plasma protein therapies: current and future perspectives
Authors:
- 1 March 2006
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 19 (1) , 243-258
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Emerging and receding risks of therapeutic regimens for haemophiliaHaemophilia, 2004
- Recombinant Human Activated Protein C in Sepsis: Assessing Its Clinical UseThe American Journal of the Medical Sciences, 2004
- West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus dataTransfusion, 2003
- The cost‐effectiveness of NAT for HIV, HCV, and HBV in whole‐blood donationsTransfusion, 2003
- Therapeutic rationale for antithrombin III in sepsisCritical Care Medicine, 2000
- Life expectancy of Swedish haemophiliacs, 1831–1980British Journal of Haematology, 1985
- Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-Bag SystemNew England Journal of Medicine, 1965
- CLINICAL USE OF A NEW GLYCINE-PRECIPITATED ANTIHEMOPHILIC FRACTIONThe American Journal of the Medical Sciences, 1965
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946
- The pathogenesis of hereditary hæmophiliaThe Journal of Pathology and Bacteriology, 1911